BRIEF: MedBot reports strong year-to-date sales as commercialization accelerates
Shanghai MicroPort MedBot (Group) Co. Ltd. (2252.HK) said on Wednesday that cumulative orders for its core products, including laparoscopic, orthopedic, and vascular intervention surgical robots, surpassed 170 units as of this week.
Orders for its flagship product, the Toumai laparoscopic surgical robot, exceeded 100 units alone, with nearly 80 delivered worldwide, making it the dominant domestic player for such products. The company emphasized that its commercialization process has entered an accelerated phase.
Toumai is the first domestically developed laparoscopic robotic system to enter the global market. Overseas orders topped 60 units across 40 countries and regions spanning Asia, Europe, Africa, Oceania and South America, the company said.
Shares of MedBot opened down 1% at HK$32.86 on Thursday. The stock is up 250% since the beginning of the year.
By Lau Chi Hang
To subscribe to Bamboo Works weekly free newsletter, click here
Related Articles
RELATED ARTICLES
-
BRIEF: MicroPort ‘s revenue soars in first half of 2025
2252.HK -
Feihe’s sliding profits point to China dairy market past its sell-by date
6186.HK
-
BRIEF: EHang reports wider loss, slashes 2025 revenue guidance
EH.US
-
BRIEF: TCL reports strong first-quarter growth on popularity of large TVs
1070.HK
-
BRIEF: Meitu reports strong profit growth in first half of 2025
1357.HK
- China’s robotaxi commercialization faces hidden barriers
-
Tuya accelerates AI strategy with 93% of shipped products featuring full AI integration
TUYA.US 2391.HK
